May 2026 Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cance
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
May 2026 Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cance
-
ナレーター：
-
著者：
This study evaluates the clinical potential of daraxonrasib, a novel oral medication designed to inhibit the RAS mutations that drive growth in over 90% of pancreatic cancers. By targeting the active "on" state of these proteins, the drug demonstrated significant antitumor activity in patients whose cancer had progressed after previous treatments, showing particularly promising objective response rates and survival metrics in those with specific genetic variants. While the therapy effectively hindered tumor progression, researchers noted a high frequency of treatment-related adverse events, such as skin rashes and gastrointestinal issues, with approximately one-third of participants experiencing more severe side effects. Ultimately, the trial establishes a phase 3 dosage and highlights daraxonrasib as a hopeful, though intensive, alternative to currently limited standard-of-care therapies for advanced pancreatic ductal adenocarcinoma.